Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
82 hedge funds and large institutions have $395M invested in Blueprint Medicines in 2016 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 5 reducing their positions, and 7 closing their positions.
860% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 5
171% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 7
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
23% more capital invested
Capital invested by funds: $322M → $395M (+$73.2M)
17% more funds holding
Funds holding: 70 → 82 (+12)
97% less call options, than puts
Call options by funds: $1K | Put options by funds: $32K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$11.1M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.05M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$4.63M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.11M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$22.8M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.02M |
| 3 |
Goldman Sachs
New York
|
-$853K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$849K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$535K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
BNP Paribas Financial Markets
Paris,
France
| $15.9K | +$14.2K | +784 | New |
|
77
Barclays
London,
United Kingdom
| $7K | +$3.63K | +200 | +154% |
|
|
HTC
78
Hershey Trust Company
Hershey,
Pennsylvania
| $6K | +$5.43K | +299 | New |
|
|
CPIG
79
Chicago Partners Investment Group
Chicago,
Illinois
| $4K | – | – | – |
|
80
Creative Planning
Overland Park,
Kansas
| $2K | – | – | – |
|
|
AIS
81
Accurate Investment Solutions
Seven Fields,
Pennsylvania
| $2K | +$1.82K | +100 | New |
|
82
Simplex Trading
Chicago,
Illinois
| $1K | +$1.38K | +76 | New |
|
|
RCM
83
RA Capital Management
Boston,
Massachusetts
| – | -$1.02M | -56,442 | Closed |
|
|
84
Goldman Sachs
New York
| – | -$853K | -47,238 | Closed |
|
|
85
Ameriprise
Minneapolis,
Minnesota
| – | -$849K | -47,014 | Closed |
|
|
SM
86
Sabby Management
Miami Beach,
Florida
| – | -$535K | -29,624 | Closed |
|
|
TI
87
Trexquant Investment
Stamford,
Connecticut
| – | -$401K | -22,216 | Closed |
|
|
ARTA
88
A.R.T. Advisors
New York
| – | -$194K | -10,791 | Closed |
|
|
TRCT
89
Tower Research Capital (TRC)
New York
| – | -$28K | -1,535 | Closed |
|
BPMC Hedge Fund Activity: Q2 2016 in Review
82 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2016, worth a combined $395M — up 23% from $322M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BPMC positions and 7 closed out — a net gain of 12 holders — while 48 added to existing stakes and 5 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $11.1M. The largest seller was Visium Asset Management, cutting an estimated $22.8M.
- 82 institutional investors held Blueprint Medicines (BPMC) as of Q2 2016, up from 70 in Q1 2016.
- Funds reported $395M of Blueprint Medicines stock for Q2 2016, up 23% quarter-over-quarter.
- 19 funds opened new Blueprint Medicines positions in Q2 2016 and 7 closed out, a net change of +12 holders.
- The largest Blueprint Medicines buyer in Q2 2016 was Wellington Management Group, an estimated $11.1M added.
- The largest Blueprint Medicines seller in Q2 2016 was Visium Asset Management, an estimated $22.8M sold.
Based on aggregated 13F filings for Q2 2016.